Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04394416 · ClinicalTrials.gov registry record · Phase 3
Trial of Imatinib for Hospitalized Adults With COVID-19
A Phase 3 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 3
- Development phase
- 21
- Enrollment target
NCT04394416 is a Phase 3 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 21 participants.
The verdict
NCT04394416, a Phase 3 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study is a randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19
Interventions
- DRUG Placebo oral tablet
- DRUG Imatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-06-02 |
| Est. Completion | 2025-07-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04394416
The ClinicalTrials.gov registry entry for NCT04394416 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04394416 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04394416 about?
NCT04394416 is a clinical study titled "Trial of Imatinib for Hospitalized Adults With COVID-19". This study is a randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19
What is the current status of trial NCT04394416?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 21 participants. The study started on 2020-06-02. Estimated completion is 2025-07-17.
What interventions are being tested in trial NCT04394416?
The interventions under investigation include: Placebo oral tablet (DRUG), Imatinib (DRUG).
Who is sponsoring clinical trial NCT04394416?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.